Filing Flows › Monte Rosa Therapeutics (GLUE) › Q2 2026
Monte Rosa Therapeutics (GLUE) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 6, 2026
Monte Rosa Therapeutics (GLUE) reported revenue of $9.0M for the second quarter 2026 (Q2 2026), -61% from a year earlier and +113% from the quarter before. Operating margin was -547.8%, net loss $43.4M (483.9% of revenue).
Monte Rosa Therapeutics, Q2 2026: revenue $9.0M (-61% year over year), operating margin -547.8%, net loss $43.4M, operating cash flow −$44.1M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $9.0M | +113% | -61% |
| Operating profit | −$49.1M | — | — |
| Net earnings | −$43.4M | — | — |
| Operating cash flow | −$44.1M | — | — |
What changed
Revenue was $9.0M in Q2 2026, down 61% year over year and up 113% from the previous quarter.
Operating costs exceeded revenue by $49.1M, an operating margin of -547.8%. Total costs grew 50% against a revenue fall of 61%. The fastest-growing cost line was Research & development (+56%). The quarter ended with a net loss of $43.4M, narrower than the previous quarter's $44.5M loss.
Operating cash flow was −$44.1M. Non-cash charges added back $2.6M of depreciation and amortization and $6.0M of share-based compensation. Working capital and other items used $9.3M. Capital expenditures of $4.7M exceeded it, leaving free cash flow of −$48.8M.
Questions
What was Monte Rosa Therapeutics' revenue in the second quarter 2026?
Monte Rosa Therapeutics (GLUE) reported revenue of $9.0M for the second quarter 2026 (Q2 2026), -61% from a year earlier and +113% from the quarter before.
Was Monte Rosa Therapeutics profitable in the second quarter 2026?
Operating loss was $49.1M (-547.8% of revenue) and net loss $43.4M.